Investigational strategies in chronic myelogenous leukemia.
Imatinib is the cornerstone of therapy in chronic myelogenous leukemia (CML) and a model for the development of novel agents directed at specific targets. The results of imatinib therapy continue to improve with approaches such as higher doses of imatinib and, possibly, with combinations of imatinib and interferon-alpha with or without cytarabine. There are multiple targets with agents directed to them that may prove to be synergistic with imatinib. These approaches are attractive, particularly when dealing with imatinib resistant CML, to prevent resistance and improve the probability of cure. The continued understanding of the biology of CML and mechanisms of resistance to imatinib and the ability to develop target-specific therapies should lead to the increased probability of cure for most patients who have CML.
Department of Leukemia, University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA. jcortes@mdanderson.org
Jorge E
JE
Cortes
Susan M
SM
O'Brien
Francis
F
Giles
Ricardo H
RH
Alvarez
Moshe
M
Talpaz
Hagop M
HM
Kantarjian
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use; D001549:Benzamides; D019496:Cancer Vaccines; D019175:DNA Methylation; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006248:Harringtonines / Q000627:therapeutic use; D000077863:Homoharringtonine; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010087:Oxides / Q000627:therapeutic use; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use; D012106:Research; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D001152:Arsenicals; D001549:Benzamides; D019496:Cancer Vaccines; D004791:Enzyme Inhibitors; D006248:Harringtonines; D010087:Oxides; D010879:Piperazines; D011743:Pyrimidines; D000077863:Homoharringtonine; D000068877:Imatinib Mesylate; D000077237:Arsenic Trioxide